<i>In Vitro</i> and <i>In Vivo</i> Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells

2011324 citationsJournal Articlebronze Open Access

Authors

Our preclinical study supports clinical evaluation of MLN9708, alone or in combination, as a potential MM therapy.

Good health and well-being

Published in: Clinical Cancer Research

Volume 17, Issue 16, pp. 5311-5321

Field-Weighted Citation Impact: 12.84